1. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6): e577. [
DOI:10.1038/bcj.2017.53] [
PMID] [
PMCID]
2. Pulte D, Jansen L, Gondos A, Katalinic A, Barnes B, Ressing M, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLOS ONE. 2014;9(1):e85554. [
DOI:10.1371/journal.pone.0085554] [
PMID] [
PMCID]
3. Samuels AL, Beesley AH, Yadav BD, Papa RA, Sutton R, Anderson D, et al. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia. Blood Cancer J. 2014;4(8): e232. [
DOI:10.1038/bcj.2014.52] [
PMID] [
PMCID]
4. Holleman A, Cheok MH, Boer MLD, Yang W, Veerman AJP, Kazemier KM, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351(6):533-42. [
DOI:10.1056/NEJMoa033513] [
PMID]
5. Lugthart S, Cheok MH, Den Boer ML, Yang W, Holleman A, Cheng C, et al. Identification of genes associated with chemo-therapy cross-resistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell. 2005;7(4):375-86. [
DOI:10.1016/j.ccr.2005.03.002] [
PMID]
6. Szczepanek J, Pogorzala M, Jarzab M, Oczko-Wojciechowska M, Kowalska M, Tretyn A. Expression profiles of signal transduction genes in ex vivo drug-resistant pediatric acute lymphoblastic leukemia. Anticancer Res. 2012;32(2):503-6.
7. Groninger E, Meeuwsen-De Boar T, Koopmans P, Uges D, Sluiter W, Veerman A, et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res. 2002;52(1):113-8. [
DOI:10.1203/00006450-200207000-00021] [
PMID]
8. Gonzalez-Cid M, Cuello MT, Larripa I. Comparison of the aneugenic effect of vinorelbine and vincristine in cultured human lymphocytes. Mutagenesis 1999;14(1):63-66. [
DOI:10.1093/mutage/14.1.63] [
PMID]
9. Ceppi F, Langlois-Pelletier C, Gagné V, Rousseau J, Ciolino C, De Lorenzo S, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(8):1105-1116. [
DOI:10.2217/pgs.14.68] [
PMID] [
PMCID]
10. Groninger E, Meeuwsen-De Boer GJ, De Graaf SSN, Kamps WA, De Bont ESJM. Vincristine induced apoptosis in acute lymphoblastic leukemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species?. Int J Oncol. 2002;21(6):1339-45. [
DOI:10.3892/ijo.21.6.1339] [
PMID]
11. Beesley AH, Firth MJ, Anderson D, Samuels AL, Ford J, Kees UR. Drug-Gene Modeling in Pediatric T-Cell Acute Lymphoblastic Leukemia Highlights Importance of 6-Mercaptopurine for Outcome. Cancer Res. 2013;73(9):2749-59. [
DOI:10.1158/0008-5472.CAN-12-3852] [
PMID]
12. Looi CY, Arya A, Cheah FK, Muharram B, Leong KH, Mohamad K, et al. Induction of apoptosis in human breast cancer cells via caspase pathway by vernodalin isolated from Centratherum anthelminticum (L.) seeds. PLOS ONE. 2013;8(2):e56643. [
DOI:10.1371/journal.pone.0056643] [
PMID] [
PMCID]
13. Aleem E, Arceci RJ. Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol. 2015;3:16. [
DOI:10.3389/fcell.2015.00016] [
PMID] [
PMCID]
14. Mancini F, Teveroni E, Conza GD, Monteleone V, Arisi I, Pellegrino M, et al. MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. Mol Cancer. 2017;16(1):55. [
DOI:10.1186/s12943-017-0626-7] [
PMID] [
PMCID]
15. Sheng X, Tong N, Tao G, Luo D, Wang M, Fang Y, et al. TERT polymorphisms modify the risk of acute lymphoblastic leukemia in Chinese children. Carcinogenesis. 2013;34(1):228-235. [
DOI:10.1093/carcin/bgs325] [
PMID]
16. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 2012;1824(1):68-88. [
DOI:10.1016/j.bbapap.2011.10.002] [
PMID] [
PMCID]
17. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting druges. Annual Review of Pharmacology and Toxicology. 2001; 41:53-77. [
DOI:10.1146/annurev.pharmtox.41.1.53] [
PMID]
18. Redell MS, Tweardy DJ. Targeting transcription factors in cancer: Challenges and evolving strategies. Drug Discov Today Technol. 2006;3(3):261-7. [
DOI:10.1016/j.ddtec.2006.09.010] [
PMID]
19. Lopez-Bergami P, Lau E, Ronai Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nature Reviews Cancer. 2010;10(1):65-76. [
DOI:10.1038/nrc2681] [
PMID] [
PMCID]
20. Thomas X, Campos L, Le QH, Guyotat D. Heat shock proteins and acute leukemias. Hematology. 2005;10(3):225-35. [
DOI:10.1080/10245330500093120] [
PMID]
21. Verza FA, Das U, AL, Dimmock JR, Marins M. Roles of histone deacetylases and inhibitors in anticancer therapy. Cancers (Basel). 2020;12(6):1664. [
DOI:10.3390/cancers12061664] [
PMID] [
PMCID]
22. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(Pt 20):3589-94. [
DOI:10.1242/jcs.051011] [
PMID] [
PMCID]
23. Liang X, Xin X, Qi D, Fu C, Ding M. Silencing the PIK3CA gene enhances the sensitivity of childhood leukemia cells to chemotherapy drugs by suppressing the phosphorylation of Akt. Yonsei Med J. 2019;60(2):182-190. [
DOI:10.3349/ymj.2019.60.2.182] [
PMID] [
PMCID]
24. Bartram I, Erben U, Ortiz-Tanchez J, Blunert K, Schlee C, Neumann M, et al. Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL. BMC Cancer. 2015;15:663. [
DOI:10.1186/s12885-015-1677-z] [
PMID] [
PMCID]
25. Abbaspour Babaei M, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther. 2016;10:2443-59. [
DOI:10.2147/DDDT.S89114] [
PMID] [
PMCID]
26. Hameda NAM, Ghallaba O, El-Neilyb D. Glutathione-S-transferase P1 as a risk factor for Egyptian patients with chronic myeloid leukemia. The Egyptian Journal of Haematology. 2016;41(2):65-69. [
DOI:10.4103/1110-1067.186408]
27. Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. Leukemia. 2007;21:1172-6. [
DOI:10.1038/sj.leu.2404692] [
PMID]
28. Lei J, Li Q, Gao Y, Zhao L, Liu Y. Increased PKCα activity by Rak1 overexpression is responsible for chemotherapy resistance in T-cell acute lymphoblastic leukemia-derived cell line. Sci Rep. 2016;6:33717. [
DOI:10.1038/srep33717] [
PMID] [
PMCID]
29. Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MWJ, Calvert VS, Petricoin EF, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia. 2013;27(3):560-568. [
DOI:10.1038/leu.2012.256] [
PMID] [
PMCID]
30. Renner AG, Santos CD, Recher C, Bailly C, Creancier L, Kruczynski A, et al. Polo-like kinase1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood. 2009;114(3):659-62. [
DOI:10.1182/blood-2008-12-195867] [
PMID]
31. Yakimchuk K, Iravani M, Hasni MS, Rhönnstad P, Nilsson S, Jondal M, et al. Effect of ligand-activated estrogen receptor β on lymphoma growth in vitro and in vivo. Leukemia. 2011;25(7):1103-10. [
DOI:10.1038/leu.2011.68] [
PMID]